Grifols' plasma medicines are a unique class of biologic therapies that require a lengthy and complex manufacturing process, taking up to 12 months from the time a donation is made until the medicine is ready for use by patients.
We have rigorous plasma safety and quality standards that include careful donor evaluation and screening, highly regulated handling and tracking processes, and state-of-the-art manufacturing processes. Grifols strives to go above and beyond the quality and safety standards established by US and international health authorities.
Grifols is responsible for every step in the manufacturing process, from the moment an individual donates plasma to when a medicine is ready for administration to a patient. This allows us to trace every vial of medicine back to each individual donor and donation. We are committed to ensuring donors and patients can be confident in the quality of every medicine that results from the donation of plasma.